Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17156133rdf:typepubmed:Citationlld:pubmed
pubmed-article:17156133lifeskim:mentionsumls-concept:C0001563lld:lifeskim
pubmed-article:17156133lifeskim:mentionsumls-concept:C0085151lld:lifeskim
pubmed-article:17156133lifeskim:mentionsumls-concept:C1999216lld:lifeskim
pubmed-article:17156133lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:17156133lifeskim:mentionsumls-concept:C0547047lld:lifeskim
pubmed-article:17156133lifeskim:mentionsumls-concept:C1515655lld:lifeskim
pubmed-article:17156133pubmed:issue3lld:pubmed
pubmed-article:17156133pubmed:dateCreated2007-2-20lld:pubmed
pubmed-article:17156133pubmed:abstractTextGeneration and deposition of the amyloid beta (Abeta) peptide following proteolytic processing of the amyloid precursor protein (APP) by BACE-1 and gamma-secretase is central to the aetiology of Alzheimer's disease. Consequently, inhibition of BACE-1, a rate-limiting enzyme in the production of Abeta, is an attractive therapeutic approach for the treatment of Alzheimer's disease. We have designed a selective non-peptidic BACE-1 inhibitor, GSK188909, that potently inhibits beta-cleavage of APP and reduces levels of secreted and intracellular Abeta in SHSY5Y cells expressing APP. In addition, we demonstrate that this compound can effectively lower brain Abeta in vivo. In APP transgenic mice, acute oral administration of GSK188909 in the presence of a p-glycoprotein inhibitor to markedly enhance the exposure of GSK188909 in the brain decreases beta-cleavage of APP and results in a significant reduction in the level of Abeta40 and Abeta42 in the brain. Encouragingly, subchronic dosing of GSK188909 in the absence of a p-glycoprotein inhibitor also lowers brain Abeta. This pivotal first report of central Abeta lowering, following oral administration of a BACE-1 inhibitor, supports the development of BACE-1 inhibitors for the treatment of Alzheimer's disease.lld:pubmed
pubmed-article:17156133pubmed:languageenglld:pubmed
pubmed-article:17156133pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:citationSubsetIMlld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17156133pubmed:statusMEDLINElld:pubmed
pubmed-article:17156133pubmed:monthFeblld:pubmed
pubmed-article:17156133pubmed:issn0022-3042lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:DingwallColin...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:DavisJohn BJBlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:HarrisonDavid...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:DemontEmmanue...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:HussainIshrut...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:HawkinsJulieJlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:HowesColinClld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:WayneGarethGlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:NaylorAlanAlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:CutlerLeanneLlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:BuckTaniaTlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:HilleChristop...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:WalterDarylDlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:JeffreyPhilip...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:GonzalezMaria...lld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:MichelAntonAlld:pubmed
pubmed-article:17156133pubmed:authorpubmed-author:RedshawSallySlld:pubmed
pubmed-article:17156133pubmed:issnTypePrintlld:pubmed
pubmed-article:17156133pubmed:volume100lld:pubmed
pubmed-article:17156133pubmed:ownerNLMlld:pubmed
pubmed-article:17156133pubmed:authorsCompleteYlld:pubmed
pubmed-article:17156133pubmed:pagination802-9lld:pubmed
pubmed-article:17156133pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:meshHeadingpubmed-meshheading:17156133...lld:pubmed
pubmed-article:17156133pubmed:year2007lld:pubmed
pubmed-article:17156133pubmed:articleTitleOral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.lld:pubmed
pubmed-article:17156133pubmed:affiliationNeurology and GastroIntestinal Centre of Excellence for Drug Discovery, GlaxoSmithKline Research & Development Ltd, Harlow, Essex, UK. Ishrut_2_Hussain@gsk.comlld:pubmed
pubmed-article:17156133pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17156133lld:pubmed